InVitro International Reports Growth in Non-Animal Testing Technologies Amid Regulatory Shifts
InVitro International reports modest sales growth and highlights increasing global momentum toward non-animal testing methods in cosmetics and personal care industries, signaling potential regulatory changes.
InVitro International (OTCQB: IVRO) reported first half fiscal year 2025 financial results, demonstrating continued progress in non-animal testing technologies. The company recorded sales of $440,650, representing a 4.4% increase compared to the same period in the previous fiscal year.
Despite the sales growth, net income declined by 24.7% to $49,239, which the company attributes to inflationary pressures and increased OTCQB listing costs. CEO W. Richard Ulmer emphasized the potential for expansion in non-animal test technologies, highlighting recent legislative developments in multiple regions.
The company's efforts align with a growing international trend toward eliminating animal testing in cosmetics and personal care products. Following Europe's 2013 ban on cosmetics tested on animals, Canada has recently passed similar legislation, with the United States potentially poised to follow suit.
Congressional discussions are exploring extended regulations that could mandate non-animal testing methods for over-the-counter products like shampoos and skin care items. IVRO's testing technologies, designed to provide corrosivity and irritation data correlating with animal and human test results, are strategically positioned to support these potential regulatory changes.
The company's global commercialization strategy, which includes test kits and partner laboratory services, appears well-timed to capitalize on the emerging market demand for scientifically validated alternative testing methods.